The present invention relates to a PD-1 variant having improved binding to PD-L1. In addition, the present invention relates to a method for producing and a method for screening for the PD-1 variant. A PD-1 variant of the present invention effectively inhibits binding between wild-type PD-1 and PD-L1, and thus can be expected to have penetration power and an effect of cancer death by immunocytes or a treatment effect on infectious diseases, which are far greater than those of conventional therapeutic agents for immune checkpoint inhibition and, simultaneously, can minimize the possibility of immunogenicity occurrence and, further, can promote the convenience of developing biological pharmaceutical drugs through the implementation of aglycosylation.
